<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biotech on FinanClub</title>
    <link>https://finan.club/tags/biotech/</link>
    <description>Recent content in Biotech on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 18 Aug 2023 11:31:26 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biotech/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Fri, 18 Aug 2023 11:31:26 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:71
Chances: Merck&amp;rsquo;s Phase 3 trial for WELIREG met the primary endpoint of PFS in certain advanced RCC patients. Merck&amp;rsquo;s impressive financial results, robust product portfolio, and commitment to R&amp;amp;D make it a potential consideration. Healthcare sector performance suggests potential for growth in healthcare stocks like Merck.</description>
    </item>
    
  </channel>
</rss>
